RESEARCH ARTICLE

Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors [version 1; peer review: 2 approved with reservations]

Yann Ruffieux ¹, Frédérique Chammartin¹, Anita Feller ², Kurt Schmidlin¹, Sabine Rohrmann³, Katharina Staehelin⁴, Christine Bouchardy⁵, Heiner C. Bucher^{6,7}, Barbara Hasse⁸, Matthias Cavassini⁹, Alexandra Calmy¹⁰, Gilles Wandeler ¹¹, Alexandra Scherrer⁸, Julia Bohlius¹, Matthias Egger ¹

¹Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

²National Institute for Cancer Epidemiology and Registration, Zurich, Switzerland

³Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland

⁴Cancer Registry Basel-Stadt and Basel-Landschaft, Department of Health, Basel, Switzerland

⁵Geneva Cancer Registry, Geneva University, Geneva, Switzerland

⁶Division of Infectious Diseases and Hospital Epidemiology, University of Basel, Basel, Switzerland

⁷Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, University of Basel, Basel, Switzerland

⁸Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland

⁹Division of Infectious Diseases, University of Lausanne, Lausanne, Switzerland

¹⁰Division of Infectious Diseases, University of Geneva, Geneva, Switzerland

¹¹Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

V1 First published: 09 Aug 2019, 8:1400
<https://doi.org/10.12688/f1000research.19585.1>

Latest published: 09 Aug 2019, 8:1400
<https://doi.org/10.12688/f1000research.19585.1>

Abstract

Background: Since the advent of combination antiretroviral therapy (cART), non-AIDS defining malignancies (NADM) have become increasingly important. We examined risk factors for NADM, including immunological, virological and socio-behavioral characteristics.

Methods: We linked the Swiss HIV Cohort Study (SHCS) with cancer registries to identify incident cancers between 1996 and 2012. We analyzed four common NADM: anal, lung, prostate, and liver cancer. We calculated standardized incidence ratios (SIRs) and assessed the effect of time-updated CD4 and CD8 count, CD4/CD8 ratio, and HIV viral load (copies/ml) in Cox regression models. We lagged time-dependent variables for 12, 24, and 36 months and captured cumulative exposures using simple moving averages (SMA). In multivariable models, we also considered HIV transmission group, smoking, and chronic hepatitis B or C infection as potential predictors of NADM incidence.

Results. Between 1996 and 2012, 563 HIV-infected individuals developed NADM, including 70 anal, 49 lung, 44 prostate, and 36 liver cancers. Compared with the general population, the SHCS exhibited

Open Peer Review

Approval Status

	1	2
version 1
09 Aug 2019	view	view

1. **Jean-Pierre Routy** , McGill University, Montreal, Canada

2. **Keith Sigel** , Icahn School of Medicine at Mount Sinai, New York, USA

Any reports and responses or comments on the article can be found at the end of the article.

higher rates of anal (SIR 76.1, 95% Confidence interval (CI) 60.2-96.2), lung (SIR 1.98, 1.50-2.62), and liver cancer (SIR 7.28, 5.25-10.1) but similar rates of prostate cancer (SIR 1.03, 0.76-1.38). Anal cancer was associated with low CD4 cell count, high CD8 cell count, men who have sex with men, and smoking. For lung cancer, the CD8 cell count was the only significant predictor identified among the immunological and virological factors. CD4 cell count, and chronic hepatitis B and C infection were predictive of liver cancer incidence. We found no evidence of any of the immunological factors being associated with prostate cancer.

Conclusions: The importance of immunodeficiency (indexed by CD4 count) and immune senescence (indexed by CD8 count) differs across NADM. Immunodeficiency was an important risk factor for anal and liver cancer whereas immune senescence was associated with lung cancer and anal cancer.

Keywords

Non-AIDS defining cancers, cohort studies, coinfection, hepatitis

Corresponding author: Matthias Egger (matthias.egger@ispm.unibe.ch)

Author roles: **Ruffieux Y:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Chammartin F:** Formal Analysis, Methodology, Writing – Review & Editing; **Feller A:** Data Curation, Investigation, Writing – Review & Editing; **Schmidlin K:** Data Curation, Formal Analysis, Writing – Review & Editing; **Rohrmann S:** Data Curation, Writing – Review & Editing; **Stahelin K:** Data Curation, Writing – Review & Editing; **Bouchardy C:** Data Curation, Writing – Review & Editing; **Bucher HC:** Data Curation, Writing – Review & Editing; **Hasse B:** Data Curation, Writing – Review & Editing; **Cavassini M:** Data Curation, Writing – Review & Editing; **Calmy A:** Data Curation, Writing – Review & Editing; **Wandeler G:** Data Curation, Investigation, Writing – Review & Editing; **Scherrer A:** Formal Analysis, Investigation, Methodology, Writing – Review & Editing; **Bohlius J:** Conceptualization, Investigation, Writing – Review & Editing; **Egger M:** Conceptualization, Funding Acquisition, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Heiner C. Bucher received grants, support for travelling, consultancy fees and honorarium from Gilead, BMS, Viiv Healthcare and Roche that were not related to this project. All other authors declare that they have no competing interests.

Grant information: The linkage and analysis of the data were funded by grants from Cancer Research Switzerland [KFS-3165-02-2013 and KFS-3862-02-2016]. The SHCS is supported by the Swiss National Science Foundation (SNSF) [177499]. ME is supported by special project funding from the SNSF [174281].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Ruffieux Y *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ruffieux Y, Chammartin F, Feller A *et al.* **Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors** [version 1; peer review: 2 approved with reservations] F1000Research 2019, 8:1400 <https://doi.org/10.12688/f1000research.19585.1>

First published: 09 Aug 2019, 8:1400 <https://doi.org/10.12688/f1000research.19585.1>

Introduction

In high-income countries, life expectancy of people living with HIV (PLWHIV) on combination antiretroviral therapy (cART) is approaching that of the general population¹. For example, in Switzerland 2006 to 2013, PLWHIV with higher education had an estimated life expectancy similar to individuals from the general population with compulsory education². Similarly, in Canada 2008 to 2012, life expectancy at age 20 years in HIV-positive people was 89% of the life expectancy in the general population³. In line with the increasing life expectancy, morbidity and mortality of PLWHIV on cART are no longer dominated by AIDS-defining events, but also affected by cardiovascular events and non-AIDS defining malignancies (NADM)^{1–5}.

An analysis of causes of death in the Data collection on Adverse events of Anti-HIV Drugs (a collaboration of eleven HIV cohort studies from Europe, the USA and Australia), found that mortality decreased from 1999 to 2011 for most causes of death, including AIDS-related, liver-related, cardiovascular and other or unknown causes⁴. However, in this collaborative study⁴ and in other cohorts^{5–7}, mortality from NADM remained stable over time. This type of cancer is now the most common cause of non-AIDS deaths in PLWHIV in high-income countries⁸. Furthermore, compared to the general population, the incidence of NADM is increased in PLWHIV, with a standardized incidence ratio for all NADM combined ranging from 1.6 to 2.8 across different studies⁹.

Several factors contribute to the higher risk of NADM among HIV-positive individuals, including prolonged exposure to immunodeficiency, a higher prevalence of smoking, and infections with oncogenic viruses such as human papilloma virus (HPV) or hepatitis B (HBV) or hepatitis C (HCV) viruses^{10–12}. Direct pro-oncogenic effects of HIV, inflammation, and coagulation pathways may also play a role^{13,14}. More recently, accelerated immune senescence, as evidenced by low ratios of CD4 to CD8 positive T cells (CD4/CD8 ratio), has been identified as a potential risk factor for NADM^{15,16}. For example, in the US Veterans Aging Cohort Study, the CD4/CD8 ratio, but not the CD4 cell count, was an independent risk factor for lung cancer¹⁵.

We linked the database of the Swiss HIV Cohort Study (SHCS) with cantonal cancer registries to examine the relative importance of different risk factors for NADM, including immunological, virological and socio-behavioral factors.

Methods

The Swiss HIV Cohort Study

The SHCS is an ongoing observational study that promotes clinical and public health research on HIV in Switzerland^{17,18}. The SHCS is a collaboration between various hospitals, clinics, laboratories, and private practices across the country. Prospective enrollment started in 1988, and involves PLWHIV aged 16 years or above. Detailed socio-demographic and behavioral parameters for each patient are collected at enrollment. Laboratory results such as CD4+ and CD8+ cell count, HIV-1 RNA viral load or indicators of exposure to hepatitis B or C virus are recorded

at enrollment and during follow-up visits. Detailed information on ART and other treatments, and of AIDS defining events are also collected at regular intervals. While NADM are recorded in the study, their ascertainment is incomplete.

Linkage to cancer registries

Incident cancers in the SHCS were identified through linkage of SHCS records with the records of the Basel, Geneva, and Zurich cantonal cancer registries. At the time of the linkage, the data covered the period up to 2012 for Geneva and Zurich, and 2011 for Basel. Only SHCS participants registered in the areas covered by the three aforementioned cancer registries were included, representing about 65% of all participants. The linkage was done using privacy-preserving probabilistic record linkage^{19,20}. Briefly, we employed a three-party protocol, with the SHCS and cancer registries collecting confidential individual-level patient data and the Institute of Social and Preventive Medicine at University of Bern serving as the independent linkage center. The linkage center supplied purpose-written encryption software²¹ that was used at SHCS centers and cancer registries to irreversibly encrypt personal identifying data (names, date of birth) using Bloom filters and calculate the similarity coefficients, which were then used to identify matching records at ISPM.

Cancers included in analyses

We supplemented the cancer cases reported in the SHCS by the cases identified through data linkage. We analyzed NADM classified according to the 10th revision of the International Classification of Diseases (ICD-10) that were diagnosed in about 40 or more patients: malignant neoplasm of anus and anal canal (C21), malignant neoplasm of liver and intrahepatic bile ducts (C22, excludes malignant neoplasm of other and unspecified parts of biliary tract), malignant neoplasm of trachea, bronchus and lung (C33–34), and prostate cancer (C61). We did not include Hodgkin lymphoma because most cases had been diagnosed in the early years of cART, when CD8 counts and viral load measurements were often missing.

Standardized incidence ratios

We calculated standardized incidence ratios (SIRs) for each identified NADM by comparing the observed number of cancers among people with HIV with the expected number of occurrences, based on age-, sex- and period-specific rates for the Swiss population provided by the National Institute for Cancer Epidemiology and Registration (indirect standardization)²². We produced 95% confidence intervals (CI) for the SIRs assuming a Poisson distribution²³.

Baseline and time-updated exposure variables

We assessed the effect of baseline and time-updated exposure variables in Cox regression models. Time-updated variables included CD4 cell count (cells/ μ L), CD8 cell count (cells/ μ L), CD4/CD8 ratio and HIV viral load (copies/mL). We updated the immunological and virological factors at the start of each month. Months with no CD4 cell count, CD8 cell count, or HIV viral load were interpolated by carrying forward or carrying back the closest measured value within 12 months, provided there

was no change in cART and no diagnosis of cancer in the interval. Time-updated bacterial pneumonia was additionally considered for lung cancer: history of bacterial pneumonia changed from no to yes when pneumonia was diagnosed. Other variables included age, likely HIV transmission group (men having sex with men [MSM], intravenous drug users [IDU], other men, other women), current smoking at enrollment (yes, no), highest completed level of education (compulsory, secondary, tertiary), chronic hepatitis B and exposure to hepatitis C (yes or no, as a time-updated variable), and calendar period (time-updated; before 2002, 2002–2007, 2008 and later). Patients were defined as having chronic hepatitis B if they had previously been tested positive for HBs-antigen or HBV-DNA, and as being exposed to hepatitis C during follow-up if they had tested positive for HCV-RNA.

Statistical analyses

We used Cox regression models for time to event analyses, measuring time from enrollment to the diagnosis of a NADM, the last clinic visit in the study period, or death, whichever came first. Follow-up time in patients enrolled before 1996, the year cART was introduced, was left truncated at 31 December 1995. Patients diagnosed with a NADM before 1 January 1996 were excluded from the analysis for that specific NADM.

In a first step, we modeled the association of the time-updated immunological and virological exposure variables (CD4 cell count, CD8 cell count, CD4/CD8 ratio, and HIV viral load) with each of the four cancers separately, adjusting for the other variables. To reduce the risk of detecting associations that reflect reverse causality, we lagged these variables for 12 months or more, and captured cumulative exposure using simple moving averages (SMA). We entered the following representations

of each variable: lagged by 12, 24 or 36 months; SMA over 12 months - lagged by 12 or 24 months; SMA over 24 months - lagged by 12 months (see [Figure 1](#)). In a next step we selected variables and representations of variables for inclusion into a final, malignancy-specific model. We selected one representation of each immunological and virological variable based on the goodness of fit (indexed by the Akaike information criteria [AIC]) and carried over variables significantly associated with cancer incidence ($P < 0.05$) when modeled separately. The intermediary and final models were adjusted for the variables age, transmission group, smoking, education, chronic hepatitis B, exposure to hepatitis C, and calendar period. The time-updated variables for bacterial pneumonia (used only in the lung cancer analysis), hepatitis B, and hepatitis C were lagged by 12 months.

We assessed proportionality assumptions of the Cox model using the Schoenfeld residuals. Results are shown as hazard ratios (HR) with 95% confidence intervals (95% CI). We imputed missing values for smoking using multivariate imputation by chained equations and pooled results of five imputed dataset. We present the analyses with imputation since results were similar to complete-case analyses. All analyses were done in **R Project for Statistical Computing** (version 3.6.0) software²⁴ using packages *survival* (version 2.42), *mice* (version 3.30) and *mitools* (version 2.3). R code and explanatory documents are available as extended data²⁵.

Results

Incidence and patient characteristics

A total of 563 incident NADM were identified in the two data sources (SHCS and cancer registries). The SHCS recorded 60.9% of all cases, and the registries 76.2%. For the cancers analyzed in this study, the completeness of recording of cases

The thick line represents the interval over which the moving average is calculated

Figure 1. Schematic representation of simple moving averages (SMAs), lagged over different periods.

in the SHCS was 54.3% for anal cancer, 66.7% for liver cancer, 71.4% for lung cancer, and 72.7% for prostate cancer. The corresponding percentages for the cancer registries were 85.7%, 80.6%, 85.7% and 93.2%, respectively (Table 1).

Anal cancer was diagnosed in 70 patients over 71,592 person-years for an incidence rate of 9.78 per 10,000 person-years (95% confidence interval [CI] 7.62-12.35). Lung cancer was diagnosed in 49 patients over 71,888 person-years (6.82 per 10,000; 95% CI 5.04-9.01), prostate cancer in 44 men over 50,322 person-years (8.74 per 10,000; 95% CI 6.35-11.74), and liver cancer in 36 patients over 71,911 person-years (5.01 per 10,000; 95% CI 3.51-6.93).

Compared to the Swiss general population, anal, lung, and liver cancer all exhibited higher rates in the SHCS, whereas the rate of prostate cancer was similar (Figure 2). The difference was largest for anal cancer: the incidence was 76 times higher in people with HIV (SIR 76.1, 95% CI 60.2-96.2) than in the general Swiss population.

Characteristics of SHCS participants who developed cancer and participants who did not are shown in Table 2. Compared to those who remained free of cancer, HIV-positive individuals, who developed cancer were slightly older, more likely to be smokers, and at a more advanced clinical stage of HIV infection

according to the Centers for Disease Control and Prevention classification²⁶. The distribution across HIV transmission groups also varied between cancers: the majority of patients who developed anal or prostate cancer were MSM, while those with lung or liver cancer were predominantly patients with a history of IDU.

Immunological and socio-behavioral risk factors

We selected one representation of each exposure variable based on goodness of fit models. The AIC values for the different models are shown in Table 3, the results of the separate models for each immunological and virological variable in Table 4 and the results of the mutually adjusted models in Table 5. For anal cancer, CD4 count, CD8 count and CD4/CD8 ratio were all associated with cancer risk in the separate models (Table 4). In the mutually adjusted model, a higher CD4 cell count (lagged 12 months) and a CD8 count below 1000 cells/ μ l (lagged by 24 months) continued to be significantly associated ($P=0.002$) with a reduced risk of anal cancer (Table 5). For example, in patients with a 12-month lagged CD4 count above 500 cells/ μ l, risk was reduced to about a fourth compared to individuals with a CD4 count below 200 cells/ μ l (hazard ratio [HR] 0.24; 95% CI 0.10-0.61). The risk of anal cancer was substantially higher in MSM (HR 6.86, 95% CI 1.64-28.6) than other men and higher in smokers (HR 2.07, 95% CI 1.07-3.98) compared to non-smokers.

Table 1. Number of individuals enrolled in the SHCS who developed a non-AIDS defining malignancy as identified through linkage to cancer registries or reported in the Swiss HIV Cohort Study (SHCS), 1996 to 2012.

Non AIDS Defining Malignancy (NADM)	Number of cases identified through linkage and in SHCS	Number of cases identified through linkage only (a)	Number of cases reported in SHCS only (b)	Total (c)	Completeness SHCS (%) [*]	Completeness registries (%) [*]
Anus	28	32	10	70	54.3	85.7
Lung	28	14	7	49	71.4	85.7
Prostate	29	12	3	44	72.7	93.2
Liver	17	12	7	36	66.7	80.6
Head and neck	7	23	2	32	28.1	93.8
Hodgkin Lymphoma	23	7	7	37	81.1	81.1
Bladder	3	9	0	12	25.0	100
Breast	9	3	4	16	81.3	75.0
Colon and Rectum	6	2	5	13	84.6	61.5
Kidney	5	0	4	9	100	55.6
Oesophagus	4	0	4	8	100	50.0
Skin Melanoma	6	13	5	24	45.8	79.2
Stomach	3	1	3	7	85.7	57.1
Testis	6	1	1	8	87.5	87.5
Other NADM	35	91	72	198	54.0	63.6
All NADM	209	220	124	563	60.9	76.2

^{*} calculated as (c-a)/c

^{*} calculated as (c-b)/c

Figure 2. The number of observed and expected incident cancer cases and standardized incidence ratios for non-AIDS defining malignancies (NADM) diagnosed among participants of the Swiss HIV Cohort Study.

For lung cancer and prostate cancer, Cox regression models were stratified by age to preserve proportional hazards. In the case of lung cancer, CD8 cell count (lagged by 36 months) was the only significant predictor ($P=0.04$) among the immunological and virological variables (Table 2): participants with CD8 cell counts equal to or above 1000 cells/ μ L had a greater risk of developing lung cancer, compared to those with counts below 1000 cells/ μ L (HR 1.89, 95% CI 1.03-3.48). A history of bacterial pneumonia was associated with lung cancer in the separate model (Table 4), but not after adjusting for CD8 cell count (Table 5). Smoking at enrollment was strongly associated with lung cancer (HR 6.50, 95% CI 1.36-31.2, Table 5). For prostate cancer, none of the immunological or virological were associated with a risk of cancer (Table 4), though there was some evidence of smoking being associated with higher rates (HR 1.92, 95% CI 0.96-3.83, Table 5).

For liver cancer, exposure to lower CD4 counts (SMA over 24 months, lagged by 12 months) and the CD4/CD8 ratio (lagged by 24 months) were associated with cancer incidence in the separate models (Table 4). In the final model (Table 5), only the CD4 cell count was predictive, with patients with average counts of 500 cells/ μ L or above at much lower risk than patients with counts below 200 cells/ μ L (HR 0.07, 95% CI 0.01-0.59). Chronic hepatitis B infection (HR 7.86, 95% CI 3.78-16.4) and hepatitis C infection (HR 4.77, 95% CI 1.80-12.7) were both strongly associated with liver cancer (Table 5).

Discussion

In the era of cART, life expectancy of PLWHIV is approaching that of the general population, the incidence of

AIDS-defining malignancies has declined sharply, and NADM have emerged as an important co-morbidity^{1,2,27,28}. This study linked the database of the SHCS with three cantonal cancer registries to identify incident NADM. Anal, lung, prostate and liver cancers were common NADM among participants of SHCS. Compared to the general population, three of the four cancers occurred more frequently among PLWHIV. The exception was prostate cancer, whose incidence was similar to the general population. Associations of lagged and cumulative exposure to immunodeficiency or immune senescence were evident for some but not all cancers, and HIV replication was not related to cancer risk.

The SHCS is a well-established cohort of people living with HIV in Switzerland, where regular follow-up visits provide a wealth of information to inform fundamental, clinical and epidemiological research^{17,18}. Both genders and the various transmission groups are well represented. We used state-of-the-art privacy preserving linkage to complement incident cancers recorded in the SHCS with cases from cantonal registries^{19,20}. Interestingly, neither the SHCS nor the cancer registries had a complete record of cases. This situation should improve in the near future, with the introduction of nationwide, compulsory cancer registration in Switzerland in 2020²⁹. Previous analyses of cancer risk in the SHCS used a matched case-control approach, which precluded the study of some risk factors^{30,31}. For example, matching cancer cases and controls on transmission group hampered the evaluation of hepatitis virus infections for liver cancer³¹, or of smoking for anal cancer³². Our study also has limitations. Cancer linkage was only possible for three cantonal registries, which meant that about 35% of SHCS participants could not be included, limiting statistical power. Anal intercourse is

Table 2. Characteristics of HIV patients who developed non-AIDS defining malignancies (NADM) and who remained free of cancer.

	Anal cancer	Lung cancer	Prostate cancer	Liver cancer	Other NADM	Free of cancer
No. of patients	70	49	44	36	315	6696
Age, mean (SD)	46.71 (8.72)	49.98 (7.71)	62.23 (7.78)	48.28 (8.41)	49.77 (10.67)	44.71 (10.51)
Female (%)	11 (15.7)	15 (30.6)	0	4 (11.1)	97 (30.8)	1980 (29.6)
Transmission group (%)						
MSM	52 (74.3)	14 (28.6)	28 (63.6)	13 (36.1)	116 (36.8)	2473 (36.9)
IDU	6 (8.6)	20 (40.8)	1 (2.3)	17 (47.2)	67 (21.3)	1675 (25.0)
Other men	3 (4.3)	6 (12.2)	15 (34.1)	6 (16.7)	68 (21.6)	1171 (17.5)
Other women	9 (12.9)	9 (18.4)	0 (0.0)	0 (0.0)	64 (20.3)	1377 (20.6)
cART >6 months (%)	61 (87.1)	37 (75.5)	36 (81.8)	27 (75.0)	239 (75.9)	5410 (80.8)
CD4 count [cells/μL] (%)						
0-199	12 (17.1)	5 (10.2)	5 (11.4)	8 (22.2)	60 (19.0)	742 (11.1)
200-349	16 (22.9)	12 (24.5)	11 (25.0)	14 (38.9)	49 (15.6)	825 (12.3)
350-499	13 (18.6)	11 (22.5)	7 (15.9)	11 (30.6)	64 (20.03)	1252 (18.7)
500+	18 (25.7)	11 (22.5)	16 (36.4)	1 (2.8)	99 (31.4)	3130 (46.7)
Missing	11 (15.7)	10 (20.4)	5 (11.4)	2 (5.6)	43 (13.7)	747 (11.2)
CD8 count [cells/μL] (%)						
0-999	30 (42.9)	25 (51.0)	24 (54.6)	27 (75.0)	184 (58.4)	4259 (63.6)
≥ 1000	29 (41.4)	14 (28.6)	15 (34.1)	7 (19.4)	88 (27.9)	1665 (24.9)
Missing	11 (15.7)	10 (20.4)	5 (11.4)	2 (5.6)	43 (13.7)	772 (11.5)
CD4/CD8 ratio (%)						
0-0.49	43 (61.4)	23 (46.9)	21 (47.7)	22 (61.1)	141 (44.8)	1928 (28.8)
0.5-1	13 (18.6)	13 (26.5)	10 (22.7)	7 (19.4)	93 (29.5)	2557 (38.2)
≥ 1	3 (4.3)	3 (6.1)	8 (18.2)	5 (13.9)	38 (12.1)	1439 (21.5)
Missing	11 (15.7)	10 (20.4)	5 (11.4)	2 (5.6)	43 (13.7)	772 (11.5)
RNA viral load [copies/mL]						
0-49	43 (61.4)	23 (46.9)	25 (56.8)	23 (63.9)	188 (59.7)	4409 (65.8)
50-499	8 (11.4)	7 (14.3)	8 (18.2)	5 (13.9)	33 (10.5)	506 (7.6)
≥ 500	9 (12.9)	8 (16.3)	5 (11.4)	6 (16.7)	51 (16.2)	961 (14.4)
Missing	10 (14.3)	11 (22.4)	6 (13.6)	2 (5.6)	43 (13.7)	820 (12.2)
Smoking at enrollment (%)						
Never	14 (20.0)	2 (4.1)	11 (25.0)	5 (13.9)	82 (26.0)	1998 (29.8)
Ever/current	53 (75.7)	40 (81.6)	30 (68.2)	26 (72.2)	203 (64.4)	3849 (57.5)
Missing	3 (4.3)	7 (14.3)	3 (6.8)	5 (13.9)	30 (9.5)	849 (12.7)
Education, highest completed (%)						
Up to compulsory	11 (15.7)	13 (26.5)	9 (20.5)	10 (27.8)	55 (17.5)	1778 (26.6)
Secondary	24 (34.3)	27 (55.1)	20 (45.5)	22 (61.1)	128 (40.6)	3063 (45.7)
Tertiary	26 (37.1)	4 (8.2)	13 (29.5)	1 (2.8)	93 (29.5)	1356 (20.3)
Other/unknown	9 (12.9)	5 (10.2)	2 (4.5)	3 (8.3)	39 (12.4)	499 (7.5)
Exposure to hepatitis C (%)	4 (5.7)	7 (14.3)	1 (2.3)	17 (47.2)	44 (14.0)	977 (14.6)
Chronic hepatitis B (%)	10 (14.3)	1 (2.0)	2 (4.5)	13 (36.1)	22 (7.0)	393 (5.9)
CDC clinical stage						
A	19 (27.1)	16 (32.7)	17 (38.6)	8 (22.2)	111 (35.2)	3423 (51.1)
B	24 (34.3)	18 (36.7)	17 (38.6)	17 (47.2)	93 (29.5)	1761 (26.3)
C	27 (38.6)	15 (30.6)	10 (22.7)	11 (30.6)	111 (35.2)	1512 (22.6)

SD, standard deviation; cART, combination anti-retroviral therapy; CDC, Centers for Disease Control and Prevention; MSM, men having sex with men; IDU, intravenous drug use.

Table 3. Akaike information criteria (AIC) of time-varying Cox models with single exposure variables.

Variable		Anus	Lung	Prostate	Liver
CD4	Lag12	826	556	526	464
	Lag24	836	555	520	458
	Lag36	831	555	523	460
	SMA12 Lag12	830	556	524	461
	SMA12 Lag24	831	555	523	455
	SMA24 Lag12	829	556	523	454
CD8	Lag12	836	553	520	468
	Lag24	830	554	518	471
	Lag36	835	551	522	471
	SMA12 Lag12	830	554	521	468
	SMA12 Lag24	833	553	522	471
	SMA24 Lag12	832	554	519	469
CD4/CD8	Lag12	827	552	525	470
	Lag24	822	553	524	467
	Lag36	830	555	525	472
	SMA12 Lag12	825	552	524	471
	SMA12 Lag24	825	554	524	469
	SMA24 Lag12	821	554	525	468
HIV-1 RNA	Lag12	818	553	520	472
	Lag24	820	550	523	470
	Lag36	822	551	520	472
	SMA12 Lag12	817	551	520	471
	SMA12 Lag24	820	554	524	472
	SMA24 Lag12	818	553	523	471

Lag12, lagged by 12 months; SMA12: simple moving average over 12 months.

Models are adjusted for age, HIV transmission group, smoking, hepatitis B and C statuses, education, and calendar year, and include only one exposure variable. Numbers in bold highlight the representations selected for analysis.

a risk factor for anal cancer, and excessive alcohol consumption for liver cancer, but data on sexual behavior and alcohol have been collected in the SHCS only since 2000 and 2005, respectively, and were not considered here.

The reasons for the higher cancer incidence in PLWHIV differ across cancers, and include multiple factors. Several studies have shown that immunodeficiency was associated with a higher risk of NADM^{28,33–35}. Some of these studies analyzed NADM as a single group, or as groups of infection-related and non-infection-related NADM. We found that immunodeficiency (indexed by exposure to low CD4 counts) was associated with anal cancer and liver cancer, but not with lung cancer or prostate cancer. Our results indicate that each NADM should be analyzed separately, rather than combining different NADM into groups.

For lung cancer, a high CD8 cell count several years prior to the diagnosis was a risk factor whereas a low CD4 count was not associated with lung cancer. Persistent CD8 cell elevation among HIV patients on long-term cART, a marker of immune senescence, is associated with inflammatory, non-AIDS related events such as cardiovascular, renal, respiratory, metabolic diseases and NADM, and with increased non-AIDS-related mortality^{36–38}. Mussini and colleagues suggested that the CD4/CD8 ratio might be a more robust marker of the immune dysfunction associated with NADM than the CD4 or the CD8 cell count³⁹. Indeed, a study of US veterans living with HIV found that the CD4/CD8 ratio was the strongest predictor of incidence with CD4/CD8 ratio ratios below 1.0 associated with higher risk¹⁵. In contrast to the veterans study, the CD8 cell count was more robustly associated with lung cancer risk than either the

Table 4. Results from separate Cox regression models for anal, lung, prostate and liver cancer and each time-updated exposure variable, adjusted for the other variables.

	Anal cancer (n=70)		Lung cancer (n=49)		Prostate cancer (n=44)		Liver cancer (n=36)	
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
CD4 cell count (cells/ μ l)		<0.001		0.28		0.80		0.001
Lag	12m		24m		24m		12m, 24m SMA	
<200	1		1		1		1	
200-349	0.58 (0.29-1.14)		1.06 (0.38-2.92) ^a		0.73 (0.26-2.00)		1.05 (0.44-2.49) ^a	
350-499	0.32 (0.15-0.68)				0.27 (0.08-0.95)			
500+	0.22 (0.11-0.46)		1.54 (0.55-4.31)		0.95 (0.38-2.36)		0.06 (0.01-0.49)	
CD8 cell count (cells/ μ l)		0.01		0.04		0.36		0.23
Lag	24m		36m		12m, 12m SMA		12m	
<1000	1		1		1		1	
1000+	1.90 (1.14-3.15)		1.89 (1.03-3.47)		1.34 (0.72-2.49)		0.64 (0.29-1.42)	
CD4/CD8 ratio		<0.001		0.17		0.93		0.015
Lag	12m, 24m SMA		12m		24m		24m	
<0.50	1		1		1		1	
0.50-0.99	0.41 (0.22-0.75)		0.99 (0.52-1.89)		0.67 (0.32-1.39)		0.51 (0.23-1.12)	
≥ 1.00	0.08 (0.01-0.59)		0.29 (0.07-1.26)		1.14 (0.50-2.61)		0.18 (0.02-1.37)	
HIV RNA (copies per ml)		0.06		0.13		0.70		0.66
Lag	12m, 12m SMA		24m		12m		24m	
<50	1		1 ^b		1		1	
50-499	1.79 (0.77-4.21)				0.24 (0.03-1.79)		0.26 (0.03-1.92)	
≥ 500	1.79 (0.96-3.33)		1.67 (0.86-3.25)		1.34 (0.62-2.90)		0.91 (0.39-2.11)	
Bacterial pneumonia (lagged 12m)	na			0.03	na		na	
No			1					
Yes			3.23 (1.13-9.24)					

^a estimate for CD4 cell count 200-499 cells/ μ l. ^b the reference category is <500 HIV RNA copies per ml.

HR, hazard ratio; CI, confidence interval; SMA, simple moving average; na, not applicable. Models for anal and liver cancer are adjusted for age, HIV transmission group, smoking, hepatitis B and C status, education, and calendar period. Models for lung cancer are stratified by age and adjusted for HIV transmission group, smoking, hepatitis C status, education, and calendar period. Models for prostate cancer are stratified for age and adjusted for HIV transmission group, smoking, hepatitis B and C status, education, and calendar period.

CD4 cell count or the CD4/CD8 ratio in our analysis, suggesting that in the cART era, immune senescence rather than immunodeficiency increases the risk of lung cancer.

A history of recurrent pneumonia was associated with lung cancer risk in the HIV/AIDS Cancer Match study⁴⁰ and in the US Veterans Aging Cohort Study¹⁵. In our analyses, the time-updated history of bacterial pneumonia was associated with lung cancer risk in the model adjusted for baseline variables, but evidence of this association disappeared after adjusting for CD8 count. Clearly, the most important risk factor for lung

cancer is smoking, which in Switzerland and elsewhere is substantially more common among PLWHIV than in the general population⁴¹⁻⁴³. Smoking was also associated with anal cancer, but it remains unclear whether the association is causal or whether smoking is a marker for unsafe sexual behavior and exposure to HPV. Several studies have found that smoking may be associated with a higher risk of HPV infection⁴⁴⁻⁴⁶.

Prostate cancer is one of the most common malignancies among men in Western populations, and an important cause of cancer death. Older age, a positive family history, black race and

Table 5. Results from final Cox regression models for anal, lung, prostate and liver cancer.

	Anal cancer (n=70)		Lung cancer (n=49)		Prostate cancer (n=44)		Liver cancer (n=36)	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Exposure variables								
CD4 cell count (cells/ μ l)		0.002						0.03
Lag	12m						12m, 24m SMA	
<200	1						1	
200-349	0.58 (0.27-1.22)						1.15 (0.47-2.81) ^a	
350-499	0.33 (0.14-0.76)							
500+	0.24 (0.10-0.61)						0.08 (0.01-0.70)	
CD8 cell count (cells/ μ l)		0.04		0.04				
Lag	24m		36m					
<1000	1		1					
1000+	1.84 (1.02-3.30)		1.89 (1.03-3.48)					
CD4/CD8 ratio		0.11						0.40
Lag	12m, 24m SMA						24m	
<0.50	1						1	
0.50-0.99	0.74 (0.36-1.52)						0.74 (0.33-1.66)	
1.00+	0.19 (0.02-1.51)						0.57 (0.07-4.44)	
Bacterial pneumonia (lagged 12m)				0.50				
No			1					
Yes			1.67 (0.39-7.10)					
Other variables								
HIV transmission group		<0.001		0.01		0.66		0.64
Other men	1		0.72 (0.23-2.24)		0.90 (0.46-1.76)		0.67 (0.24-1.87) ^b	
Intravenous drug use	1.05 (0.18-6.09)		3.44 (1.42-8.35)		0.41 (0.04-3.71)		1.05 (0.38-2.95)	
MSM	6.86 (1.64-28.59)		1		1		1	
Other women	4.92 (1.05-23.06)		2.34 (0.97-5.62)		NA			
Smoking at enrollment		0.03		0.02		0.06		0.52
No	1		1		1		1	
Yes	2.07 (1.07-3.98)		6.50 (1.36-31.2)		1.92 (0.96-3.83)		1.41 (0.51-3.95)	
Hepatitis B infection (positive for surface antigen or DNA, lagged 12m)		0.53				0.72		<0.001
No	1				1		1	
Yes	1.36 (0.54-3.43)				0.76 (0.18-3.19)		7.86 (3.78-16.4)	
Hepatitis C infection (RNA positive, lagged 12m)		0.23		0.14		0.58		0.002
No	1		1		1		1	
Yes	0.39 (0.09-1.77)		0.45 (0.16-1.30)		0.53 (0.06-4.61)		4.77 (1.80-12.7)	

^a estimate for CD4 cell count 200-499, ^b estimate for other women or men

HR, hazard ratio; SMA, simple moving average; MSM, men having sex with men.

All models are adjusted for the variables shown and for age, calendar period, and highest completed education. Models for lung cancer and prostate cancer are stratified with respect to age.

elevated levels of insulin growth factor (IGF)-I have been shown to be risk factors for prostate cancer^{47,48}. Our results do not suggest that immunodeficiency or immune senescence strongly influence prostate cancer risk. In this context, it is noteworthy that prostate cancer is not consistently responsive to immune therapy, in contrast to other solid tumors, including lung cancer⁴⁹.

Liver cancer was associated with prolonged exposure to CD4 counts below 500 cells/μl however; chronic viral hepatitis was a likely cause in almost all patients developing liver cancer: there was evidence of chronic HBV or HCV infection in 83% of patients with liver cancer. HBV and HCV were both strong risk factors for the cancer. An explanation for the strong association with HBV might be hepatitis delta virus (HDV) co-infection, which in the SHCS is observed in about 15% of patients with chronic HBV infection⁵⁰. HDV infection accelerates the progression of HBV related liver disease, including hepatocellular cancer⁵⁰.

Immunodeficiency and, to a lesser extent, immune senescence are prevented by starting cART as soon as possible after HIV diagnosis³⁶, as recommended by the World Health Organization⁵¹. The “Universal Test and Treat” approach to HIV coupled with interventions to ensure adherence will likely reduce the incidence of some NADM. The integration of smoking cessation interventions into routine care of people living with HIV is another important measure⁵². All SHCS participants are tested for chronic HBV infection to guide decisions on HBV vaccination and on the inclusion antiretrovirals with activity against HBV in cART regimens, as recommended by guidelines^{53,54}. Similarly, testing for antibodies against HCV is done at HIV diagnosis and annually thereafter, and there is universal access to direct acting anti-virus (DAA) therapy against HCV. Future analyses of the incidence of NADM in the SHCS will document the impact of these measures. Of note, the effectiveness of anal cancer screening is unclear: the ongoing Anal Cancer/HSIL Outcomes Research Study (ANCHOR) aims to determine whether treatment of high grade squamous intraepithelial lesions (HSIL) prevents anal cancer⁵⁵.

Conclusions

The importance of immunodeficiency and immune senescence, and of other risk factors differs across NADM, with important implications for prevention. Immunodeficiency was an important risk factor for anal and liver cancer whereas immune senescence was associated with lung cancer and anal cancer.

Ethics statement

The SHCS was approved by the Ethics committees of the participating institutions. At enrolment, SHCS participants provide written informed consent for the use of biological and clinical data. For the present study, we obtained additional ethical approval for privacy-preserving probabilistic record linkage from the Ethics Committee of the Canton of Bern.

Data availability

Source data

The National Institute for Cancer Epidemiology and Registration (NICER) is happy to share the anonymized cancer registry data with eligible partners. If you wish to receive specific data

from the NICER database, please complete the respective form at <https://www.nicer.org/en/data/request-data/>.

Underlying data

The data analyzed in this study are sensitive, having been contributed by people living with HIV. Access to de-identified data is restricted to collaborative projects that have been submitted to and approved by the Scientific Board of the SHCS. Please contact the SHCS at <http://www.shcs.ch/contact> if you are interested in gaining access to the study data. Sharing or linkage of data may require additional ethics approval.

Extended data

Files with the R code used in the analysis are provided as extended data, along with an explanatory document, on Open Science Framework

Open Science Framework: Extended data for Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors (Ruffieux et al. Faculty1000research 2019). <https://doi.org/10.17605/OSF.IO/GY5VM>²⁵

This project contains the following extended data:

- code.description final.pdf (description of R code)
- pilot.R (initializes data preprocessing for a given cancer)
- preprocess_SHCS.R (loads SHCS data)
- preprocess_linkage.R (loads the cases of cancer that could be linked to the SHCS)
- merge.R (appends patient-level information, creates dataset with one line per patient)
- risk_factors_monthly.R (creates dataset with one line per month, per patient, with time-updated variables)
- write_res_df.R (sets up data for survival analysis for a specific cancer)
- cancer_counts.R (produces the number of cancers per data source reported in [Table 1](#))
- patient_characteristics.R (produces results in [Table 2](#))
- crude_incidence_rates.R (produces crude cancer incidence rates)
- SIR_NADCs.R (produces the SMRs shown in [Figure 2](#))
- impute_smoking.R (multiple imputation of smoking variable)
- Cox_model_selection.R (produces the AICs in [Table 3](#)).
- risk_factors_Cox.R (Cox regression to produce results in [Table 4](#) and [Table 5](#))

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Grant information

The linkage and analysis of the data were funded by grants from Cancer Research Switzerland [KFS-3165-02-2013 and KFS-3862-02-2016]. The SHCS is supported by the Swiss National Science Foundation (SNSF) [177499]. ME is supported by special project funding from the SNSF [174281].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We are grateful to the patients, study nurses, and care providers who participate in the SHCS.

The members of the Swiss HIV Cohort Study are: Aepli-Popp K, Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy of “Positive Council”), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Rudin C, Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory Committee), Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

References

- Wandeler G, Johnson LF, Egger M: **Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population.** *Curr Opin HIV AIDS*. 2016; 11(5): 492–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gueler A, Moser A, Calmy A, *et al.*: **Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.** *AIDS*. 2017; 31(3): 427–36.
[PubMed Abstract](#) | [Free Full Text](#)
- Patterson S, Cescon A, Samji H, *et al.*: **Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.** *BMC Infect Dis*. 2015; 15: 274.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Smith CJ, Rymon L, Weber R, *et al.*: **Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.** *Lancet*. 2014; 384(9939): 241–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Antiretroviral Therapy Cohort Collaboration: **Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies.** *Clin Infect Dis*. 2010; 50(10): 1387–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Morlat P, Roussillon C, Henard S, *et al.*: **Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.** *AIDS*. 2014; 28(8): 1181–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schwarcz SK, Vu A, Hsu LC, *et al.*: **Changes in causes of death among persons with AIDS: San Francisco, California, 1996–2011.** *AIDS Patient Care STDS*. 2014; 28(10): 517–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Farahani M, Mulinder H, Farahani A, *et al.*: **Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis.** *Int J STD AIDS*. 2017; 28(7): 636–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Grulich AE, van Leeuwen MT, Falster MO, *et al.*: **Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.** *Lancet*. 2007; 370(9581): 59–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Engels EA: **Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities.** *AIDS*. 2009; 23(8): 875–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Borges AH, Dubrow R, Silverberg MJ: **Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk.** *Curr Opin HIV AIDS*. 2014; 9(1): 34–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Clifford GM, Polesel J, Rickenbach M, *et al.*: **Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.** *J Natl Cancer Inst*. 2005; 97(6): 425–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Borges AH, Silverberg MJ, Wentworth D, *et al.*: **Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers.** *AIDS*. 2013; 27(9): 1433–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Deeks SG: **HIV infection, inflammation, immunosenescence, and aging.** *Annu Rev Med*. 2011; 62(1): 141–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sigel K, Wisnivesky J, Crothers K, *et al.*: **Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study.** *Lancet HIV*. 2017; 4(2): e67–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hema MN, Ferry T, Dupon M, *et al.*: **Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study.** *Apertrei C, editor. PLoS One*. 2016; 11(8): e0161594.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ledergerber B, von Overbeck J, Egger M, *et al.*: **The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics.** *Soz Präventivmed*. 1994; 39(6): 387–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Swiss HIV Cohort Study, Schoeni-Affolter F, Ledergerber B, *et al.*: **Cohort profile: the Swiss HIV Cohort study.** *Int J Epidemiol*. 2010; 39(5): 1179–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schmidlin K, Clough-Gorr KM, Spoerri A, *et al.*: **Privacy preserving probabilistic record linkage (P3RL): a novel method for linking existing health-related data and maintaining participant confidentiality.** *BMC Med Res Methodol*. 2015; 15: 46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schnell R, Bachteler T, Reiher J: **Privacy-preserving record linkage using Bloom filters.** *BMC Med Inform Decis Mak*. 2009; 9: 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schmidlin K, Clough-Gorr KM, Spoerri A, *et al.*: **Privacy preserving probabilistic record linkage (P3RL): a novel method for linking existing health-related data and maintaining participant confidentiality.** *BMC Med Res Methodol*. 2015; 15: 46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- National Institute for Cancer Epidemiology and Registration [Internet].
[Reference Source](#)
- Breslow N, Day N: **Statistical methods in cancer research. Volume II: The design and analysis of cohort studies.** Vol. 2, IARC Scientific Publications No. 82. Lyon, France: Oxford University Press; 1987.
[Reference Source](#)
- R Development Core Team: **R: A language and environment for statistical computing.** R Foundation for Statistical Computing, Vienna, Austria. 2010.
[Reference Source](#)
- Egger M: **Extended data for Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors (Ruffieux *et al.* Faculty1000research 2019).** 2019.
<http://www.doi.org/10.17605/OSF.IO/GY5VM>
- Acquired immunodeficiency syndrome (AIDS). 1987 revision of CDC/WHO case definition for AIDS. *Wkly Epidemiol Rec*. 1988; 63: 1–7.
[Reference Source](#)
- Shiels MS, Engels EA: **Evolving epidemiology of HIV-associated malignancies.** *Curr Opin HIV AIDS*. NIH Public Access; 2017; 12: 6–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

28. Mazzotta E, Tontodonati M, Gabrielli C, *et al.*: **Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy.** *J Int AIDS Soc.* 2014; **17**(4 Suppl 3): 19652.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Office fédéral de la santé publique OFSP: **Enregistrement du cancer** [Internet]. [cited 2019 Jan 6].
[Reference Source](#)
30. Clifford GM, Lise M, Franceschi S, *et al.*: **Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection.** *Br J Cancer.* 2012; **106**(3): 447–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Clifford GM, Rickenbach M, Polesel J, *et al.*: **Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.** *AIDS.* 2008; **22**(16): 2135–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Bertisch B, Franceschi S, Lise M, *et al.*: **Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study.** *Am J Epidemiol.* 2013; **178**(6): 877–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Pacheco YM, Jarrin I, Rosado I, *et al.*: **Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.** *Antiviral Res.* 2015; **117**: 69–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Kesselring A, Gras L, Smit C, *et al.*: **Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy.** *Clin Infect Dis.* 2011; **52**(12): 1458–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Guiguet M, Boué F, Cadranet J, *et al.*: **Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.** *Lancet Oncol.* 2009; **10**(12): 1152–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Cao W, Mehraj V, Kaufmann DE, *et al.*: **Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era.** *J Int AIDS Soc.* 2016; **19**(1): 20697.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Trickey A, May MT, Schommers P, *et al.*: **CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).** *Clin Infect Dis.* 2017; **65**(6): 959–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Helleberg M, Kronborg G, Ullum H, *et al.*: **Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals.** *J Infect Dis.* 2015; **211**(11): 1726–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Mussini C, Lorenzini P, Cozzi-Lepri A, *et al.*: **CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.** *Lancet HIV.* 2015; **2**(3): e98–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Shebl FM, Engels EA, Goedert JJ, *et al.*: **Pulmonary infections and risk of lung cancer among persons with AIDS.** *J Acquir Immune Defic Syndr.* 2010; **55**(3): 375–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Calvo-Sánchez M, Perelló R, Pérez I, *et al.*: **Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case-control studies.** *HIV Med.* 2013; **14**(1): 40–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Crothers K, Goulet JL, Rodríguez-Barradas MC, *et al.*: **Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans.** *AIDS Educ Prev.* 2009; **21**(3 Suppl): 40–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Gmel G, Kuendig H, Maffli E, *et al.*: **Suchtmonitoring Schweiz. Jahresbericht – Daten 2011.** Bern; 2012.
[Reference Source](#)
44. Vaccarella S, Herrero R, Snijders PJ, *et al.*: **Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys.** *Int J Epidemiol.* 2008; **37**(3): 536–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Wieland U, Hellmich M, Wetendorf J, *et al.*: **Smoking and anal high-risk human papillomavirus DNA loads in HIV-positive men who have sex with men.** *Int J Med Microbiol.* 2015; **305**(7): 689–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Combes JD, Heard I, Poizat-Martin I, *et al.*: **Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men.** *J Infect Dis.* 2018; **217**(10): 1535–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Grönberg H: **Prostate cancer epidemiology.** *Lancet.* 2003; **361**(9360): 859–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Renehan AG, Zwahlen M, Minder C, *et al.*: **Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.** *Lancet.* 2004; **363**(9418): 1346–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Slovin SF: **Immunotherapy for prostate cancer: is prostate an immune responsive tumor?** *Curr Opin Urol.* 2016; **26**(6): 529–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Béguelin C, Moradpour D, Sahli R, *et al.*: **Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.** *J Hepatol.* 2017; **66**(2): 297–303.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. World Health Organization: **Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach.** Second Edition 2016. Geneva; 2016.
[Reference Source](#)
52. Goncalves PH, Montezuma-Rusca JM, Yarchoan R, *et al.*: **Cancer prevention in HIV-infected populations.** *Semin Oncol.* 2016; **43**(1): 173–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Masur H, Kaplan JE, Holmes KK, *et al.*: **Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.** *Ann Intern Med.* 2002; **137**(5 Pt 2): 435–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. EACS European AIDS Clinical Society: **Guidelines. Version 9.1. October 2018.**
[Reference Source](#)
55. **Anchor Trial Launch.** National Cancer Institute [Internet]. [cited 2019 Jan 7].
[Reference Source](#)

Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 23 September 2019

<https://doi.org/10.5256/f1000research.21474.r52874>

© 2019 Sigel K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keith Sigel

Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

This is an interesting and well written manuscript describing a study evaluating the incidence of non-AIDS cancers as well as association of longitudinal measures of immunologic and infectious exposures in the Swiss HIV Cohort. The study identifies immunologic risk factors for several NADCs, some of which differ from previous studies. The authors found higher risks of several NADCs in HIV+ persons but not prostate cancer, generally similar findings to other large population-based studies. Specific immunologic disturbances were different for the more prevalent cancers (i.e., low CD4/high CD8 for anus). This analysis utilizes rigorous and well-described methods and is a useful comparison for other similar studies from other cohorts.

Introduction:

- "This type of cancer is now the most .. " -- this should probably be plural (these types of cancer)
- You might want to define "cantonal" - it is not a well-known word

Discussion:

- You say that " immune senescence rather than immunodeficiency increases the risk of lung cancer." This needs additional justification and/or support (and likely is too strong of a statement) as you would need additional phenotyping of these CD8s (i.e., additional flow markers) to definitively say that there is a increase in senescence. This also may need to be tempered in the conclusion. If you can provide good evidence that excess CD8s indicates senescence (as opposed to activation or other phenotypic states) then that would also likely suffice.
- This study had far fewer lung cancers than the VACS study - that should be mentioned; for the lung finding at the very least and potentially for any other findings that contract other large studies a power calculation should be performed to determine the minimum effect

that could be detected for CD4, CD4/CD8 and/or pneumonia based on the numbers of cancer cases. Also for the lung findings, it would be useful to compare to the French studies that have evaluated similar immunologic exposures and found associations with CD4/CD8 and longitudinal CD4 level.

- Lack of pack-year smoking exposure information should be included as a limitation.
- A minor criticism is that the data is not available for confirmation due to its sensitive nature. This is understandable and does not need to be addressed.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: I was the lead author in the similar study from the Veterans Aging Cohort Study that was cited in this study; this paper uses very similar methods to our paper.

Reviewer Expertise: HIV and cancer risk/outcomes

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 03 September 2019

<https://doi.org/10.5256/f1000research.21474.r52261>

© 2019 Routy J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

? Jean-Pierre Routy

Research Institute of the McGill University Health Centre, Chronic Viral Illness Service, and Division of Hematology, McGill University, Montreal, QC, Canada

Non-AIDs cancers seem to be more frequent in well-treated patients on ART than the general population, due either to HIV persistent immune damage vs. lifestyle, behaviour risk or both. To prove this link, HIV infected persons should be compared to age matched general population in a relatively large population as the events remain encouragingly relatively low, during the ART era, where viral replication is controlled over long periods of time.

To this end, investigators from the well-established HIV Swiss cohort calculated standardized incidence ratios for each identified NADM by comparing the observed number of cancers with the expected number of occurrences. An indirect standardization was performed using period-specific rates for the Swiss population provided by the National Institute for Cancer Epidemiology and Registration using age and sex as co-variables. Influence of CD4 and CD8 count, CD4/CD8 ratio, and HIV viral load was assessed by Cox regression models.

Higher rates of HPV driven anal (SIR 76.1, 95% Confidence interval (CI) 60.2-96.2), lung (SIR 1.98, 1.50-2.62), and liver cancer (SIR 7.28, 5.25-10.1) were observed.

Hormonally driven cancer like prostate cancer was similar in HIV and control population (SIR 1.03, 0.76-1.38).

Interestingly, anal cancer was associated with low CD4, with high CD8, and smoking.

Interestingly, for lung cancer, CD8 cell count was the only predictor identified opening new hypothesis on inflammation in the context of ART-treated persons. As expected, CD4 cell count and chronic hepatitis B and C infection were predictive of liver cancer incidence.

Several issues should be addressed:

- Types of cancer should be divided into viral-related and those not known to be associated with viruses like lung and prostate.
- Focus should be on lung cancer and its relationship with CD8 and nadir CD4 T cell if data available.
- Effort should be on novelty and not confirming previous data.
- Changes occurring or not in cancer incidence during the study period should be highlighted.
- Discussion on Cd8 elevation and occurrence of lung cancer should be more detailed as future direction for research.

Conclusion:

Immunodeficiency was an important risk factor for anal and liver cancer, whereas immune senescence was associated with lung cancer and anal cancer. I think anal cancer with immune senescence should be removed from the conclusion as it seems to be more driven by CD4 T cells and the conclusion is not clear. Findings of lung cancer and immune senescence are the novelty of this manuscript and open several hypothesis including smoking and CD8 elevation in non-HIV population and immune senescence linked with CMV serostatus.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research